source
- Relay Therapeutics' zovegalisib shows 60% response in mid‑stage trial for rare vascular anomaliesRelay Therapeutics reported early data from a phase 2 trial of its experimental drug zovegalisib in patients with vascular anomalies, a group of rare disorders characterized by abnormal blood vesse…
- FDA approves AstraZeneca’s novel hypertension pill BaxfendyThe U.S. Food and Drug Administration has cleared AstraZeneca’s new hypertension medication, Baxfendy, marking the first approval of a drug that works by inhibiting a blood‑pressure‑raising enzyme.…